Century Therapeutics, Inc. (IPSC) Free cash flow
- Free cash flow · 12 months (USD): Value $-88.09M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-88.09M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-86.76M − $1.33M ≈ $-88.09M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-86.76M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.79× | Operating cash flow / net income. Period ending 2026-06-30. $-86.76M ÷ $-109.79M ≈ 0.79× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -86.76M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 1.33M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -88.09M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -109.79M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-88.09M | (m) | $-86.76M | $1.33M | (m) | (m) | (m) | $-109.79M | (m) | (m) | (m) | 0.79× |
| 2026-03-31 | $-95.47M | (m) | $-94.52M | $957.00K | (m) | (m) | (m) | $-107.78M | (m) | (m) | (m) | 0.88× |
| 2025-12-31 | $-104.72M | (m) | $-103.88M | $848.00K | (m) | $109.16M | (m) | $-9.58M | (m) | (m) | -95.93% | 10.84× |
| 2025-09-30 | (m) | (m) | $-112.02M | (m) | (m) | $113.34M | (m) | $-26.48M | (m) | (m) | (m) | 4.23× |
| 2025-06-30 | $-114.91M | (m) | $-114.77M | $142.00K | (m) | $114.13M | (m) | $-23.28M | (m) | (m) | -100.69% | 4.93× |
| 2025-03-31 | $-114.60M | (m) | $-114.51M | $90.00K | (m) | $114.90M | (m) | $-21.94M | (m) | (m) | -99.74% | 5.22× |
| 2024-12-31 | $-110.29M | (m) | $-110.14M | $154.00K | (m) | $6.59M | (m) | $-126.57M | (m) | (m) | -1673.84% | 0.87× |
| 2024-09-30 | (m) | (m) | $-112.14M | (m) | (m) | $2.68M | (m) | $-129.89M | (m) | (m) | (m) | 0.86× |
| 2024-06-30 | $-102.51M | (m) | $-97.46M | $5.05M | (m) | $2.04M | (m) | $-131.39M | (m) | (m) | -5022.44% | 0.74× |
| 2024-03-31 | $-98.66M | (m) | $-89.38M | $9.28M | (m) | $1.37M | (m) | $-133.47M | (m) | (m) | -7201.53% | 0.67× |
| 2023-12-31 | $-102.08M | (m) | $-88.35M | $13.74M | (m) | $2.23M | (m) | $-136.67M | (m) | (m) | -4567.52% | 0.65× |
| 2023-09-30 | $-104.05M | (m) | $-85.03M | $19.02M | (m) | $2.49M | (m) | $-128.96M | (m) | (m) | -4182.03% | 0.66× |
| 2023-06-30 | $-121.19M | (m) | $-95.61M | $25.57M | (m) | $4.56M | (m) | $-126.99M | (m) | (m) | -2655.24% | 0.75× |
| 2023-03-31 | $-133.45M | (m) | $-101.92M | $31.53M | (m) | $5.86M | (m) | $-124.68M | (m) | (m) | -2276.88% | 0.82× |
| 2022-12-31 | $-16.55M | (m) | $14.05M | $30.60M | (m) | $5.20M | (m) | $-130.93M | (m) | (m) | -318.37% | -0.11× |
| 2022-09-30 | $-28.45M | (m) | $12.61M | $41.06M | (m) | (m) | (m) | $-127.44M | (m) | (m) | (m) | -0.10× |
| 2022-06-30 | $-34.12M | (m) | $12.86M | $46.98M | (m) | (m) | (m) | $-122.70M | (m) | (m) | (m) | -0.10× |
| 2022-03-31 | $-27.22M | (m) | $19.93M | $47.15M | (m) | (m) | (m) | $-114.99M | (m) | (m) | (m) | -0.17× |
| 2021-12-31 | $-133.97M | (m) | $-89.00M | $44.97M | (m) | (m) | (m) | $-95.82M | (m) | (m) | (m) | 0.93× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-62.25M | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-51.09M | (m) | $-41.27M | $9.82M | (m) | (m) | (m) | $-53.58M | (m) | (m) | (m) | 0.77× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |